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LEUKEMIC BLAST CELLS AND CONTROVERSIES 
IN MODELS OF HEMATOPOIESIS
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Classical and up-to-date models of hematopoietic lineage determination are briefly reviewed with the focus on myeloid-based 
models challenging the existence of the common progenitor for T cells, B cells and NK cells. The analysis of immunophenotype 
of leukemic blast cells seems to be a promising approach for interpreting some controversies in the schemes of normal hematopoi-
esis. The lite rature data as well as our own findings in the patients with various types of acute leukemias are in favor of the concept 
postulating that common myeloid-lymphoid progenitors giving rise to T and B cell branches retain the myeloid potential. The si-
milarity of some immunophenotypic features of blast cells in pro-B acute lymphoblastic leukemia and acute monoblastic leukemia 
is consistent with monocyte origin postulated in the studies of normal hematopoiesis. Study of acute leukemias may be the chal-
lenging area of research allowing for new insight into the origin of hematopoietic cell lineages.
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HISTORICAL BACKGROUND
Unitary theory of hematopoiesis put forward by A. Ma-
ximow more than a century ago has an exceptional place 
in the history of oncohematology [1]. Based on his semi-
nal experimental histological findings, A. Maxi mow was 
the first to postulate the existence of a single parental cell 
common for all three lineages of hematopoiesis, namely 
lymphoid, myeloid and erythroblastoid. While the question 
whether or not all blood cells derive from a single precursor 
cell was a subject of consi derable debate over the years, 
now the monophyletic view of hematopoiesis became 
generally accepted.
In 1961, the unequivocal evidence proving existence 
of hematopoietic stem cell (HSC) was obtained in stu-
dies with bone marrow in lethally irradiated mice [2]. HSC 
has been considered as a pluripotent cell being capable 
of self-renewal and giving rise to the progenitor cells of all 
lineages of hematopoiesis. Later on, HSC population has 
been shown to be heterogeneous subdividing into long-
term HSCs and short-term HSCs [3]. While originally HSCs 
were delineated only based on the clonal assays, later they 
became phenotypically distinguishable [4].
According to the current models of lineage determina-
tion in the hematopoietic hierarchies, HSC diffe rentiation 
gives rise to multipotent progenitors (MPPs) practically 
devoid of self-renewal ability but retaining the potential 
for multilineage differentiation. In the classical dichotomy 
concept, MPP was thought to give rise to two principal 
lineages of hematopoiesis, namely lymphoid and myeloid-
erythroid. Later, hypothetical lineage-restricted pro-
genitors, such as common myeloid progenitor (CMP) and 
common lymphoid progenitor (CLP) have been identified 
in experimental studies of hematopoiesis in mice [5, 6].
Classical dichotomic model of myeloid-lymphoid 
branching vs. myeloid-based model. In classical di-
chotomic model reinforced by identification of CMP and 
CLP, lymphoid and myeloid lineages diverge from MPP 
as a single progenitor in a symmetrical fashion [7]. There-
fore, CMP and CLP were regarded as myeloid or lymphoid 
lineage committed progenitors. Nevertheless, the classi-
cal dichotomic model was later modified since the experi-
mental findings suggest that CLP and CMP are generated 
asymmetrically from different MPPs. In fact, MPPs turned 
out to be heterogeneous containing the progenitors 
generating two types of cells and those generating only 
one type, in addition to progenitors generating myeloid, 
T and B cells with varying combinations of lymphoid and 
myeloid potential [8]. Moreover, prior to lymphoid lineage 
commitment at CLP stage, MPPs lose myeloid lineage 
differentiation potential in a stepwise fashion. Kawamoto 
et al. [9] pointed out that lymphoid lineage specification 
is in fact a gradual process with many intermediate states 
rather than a pathway with single bifurcation.
The origin of T, B, and NK cell lineages: common 
or separate progenitors? According to the classical 
model, CLP is a single progenitor committed to lymphoid 
lineages, namely T, B or NK cells. In other words, the exi-
stence of a single progenitor suggested a common origin 
of all lymphocytes rather than a separate developmental 
pathway for each lymphocyte lineage from HSCs. In clas-
sical schemes of hematopoiesis, the direct dichotomy 
of B cell progenitors and T cell progenitors from CLP 
was postula ted [10]. Instead, the myeloid-based model 
introduces common myeloid-lymphoid progenitor (CMLP) 
giving rise to T and B cell branches that retain the myeloid 
potential [9]. The postulated CMLP generates T and B cell 
progenitors through bipotential myeloid/T progenitor and 
myeloid/B progenitor stages, respectively [11]. Acco rding 
to the revised models, CMP gives rise to well-defined 
populations of myelo-erythroid progenitors:  granulocyte/
macrophage progenitor (GMP) and megakaryocyte/
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erythrocyte progenitor (MEP) while the existence of CLP 
as a progenitor with restricted B and T cell output has 
not been confirmed and MLP (multilymphoid progenitor) 
gi ving rise to lymphoid and myelo-monocytic lineages 
was placed instead of CLP in the scheme of human he-
matopoiesis [12, 13]. Nevertheless, the precise lineage 
output of each suggested MLP and the precise points 
of bran ching of B, T and NK cell lineages could not 
be ascertained. The cells possessing the mixed T/B po-
tential were not found out [11]. Moreover, several studies 
indicate that the divergence of T cell lineage might occur 
upstream of CLPs in mouse bone marrow [7]. Neverthe-
less, the  exact point of bifurcation giving rise to T cells 
remains highly questionable.
The exact origin of NK cells also remains questionable. 
It is still unknown whether the postulated T/NK progenitor 
exists. While the prevalent idea of common T/NK pathway 
is supported by a series of the shared T/NK antigens and 
the similarity of some functions in T and NK cells, a clo-
nogenic lymphoid progenitor with both B cell and NK cell 
lineage potential has been also identified [14]. This sug-
gests that NK cell pathway may be closer to B cell rather 
than T cell pathway, and these relations are in fact depicted 
in some revised schemes of hematopoiesis [12].
Novel myeloid-based model of hematopoiesis 
and origin of granulocytes, macrophages, and den-
dritic cells. Since the classical model of hematopoiesis 
postulating a dichotomous lineage restriction of MPPs 
into CLPs and CMPs has been challenged by the identi-
fication of lymphoid progenitors retaining partial myeloid 
potential such as MLPs in human hematopoiesis, it was 
suggested that some cells belonging to myeloid lineage 
might originate from both myeloid and lymphoid (with 
myeloid potential) branches [15]. A close relationship 
between B cells and macrophages has been suggested 
earlier from the findings that B cells and B-cell lines can 
be converted into macrophages in transfection experi-
ments [16]. Doulatov et al. [13] presented evidence that 
MLPs generate not only all lymphoid cell types but also 
monocytes, macrophages and dendritic cells (DCs). 
In other words, macrophages and DCs can be derived 
from both MLPs and GMPs. All these data prompted once 
again a revision of the model of hematopoiesis.
HSC and leukemic stem cell (LSC). The hierarchic 
relationships in hematopoietic system have been suc-
cessfully delineated due to the functional assays based 
on clonogenic analysis and later on the subtle analysis 
of immunophenotype of various subpopulations of HSC 
and progenitor cells. Nevertheless, the interpretation 
of in vitro assays could not be regarded as unequivocal 
due to various technical factors intrinsic to these assays. 
Some uncertainties in establishing precise lineage poten-
tial and deline ating the exact branching points for each 
lineage as well as presumable pathways and postulated 
progenitors are demonstrated in various modern modified 
variants of hematopoiesis schemes [7, 9, 12]. In fact, the 
detailed features of certain pathways of hematopoiesis 
and existence of several progenitor cells remain the point 
of much controversy. Moreover, despite the obvious prog-
ress in understanding the functional properties, molecular 
mechanisms of regulation of proliferation of HSCs and 
hematopoietic progenitor cells, their cytomorphological 
and cytochemical features remain underexplored.
In 1997, in a series of meticulous experiments the exi-
stence of the LSC was proved for acute myelo blastic 
leukemia [17]. Later on, LSCs for several other biological 
forms of leukemias have been identified. Now it is widely 
recognized that LSC in each type of leukemia corresponds 
to one or another normal counterpart representing pro-
genitor cells at various stages of lineage commitment 
and differentiation in the hie rarchy of hematopoiesis. 
In the recent WHO classification of tumors of hemato-
poietic and lymphoid tissues (2008), the candidate LSCs 
suggested for each form of leukemias are compared with 
corresponding stem cells and progenitor cells in normal 
hematopo iesis [18]. It has been shown that LSCs and 
HSCs share the gene expression programs [19].
Now it is generally assumed that the study of leukemic 
analogs of progenitor cells in different biological types 
of leukemias will be much helpful in elucidating some 
questionable points in modern scheme of hematopoiesis. 
The analysis of the blast cells in the patients with hemato-
logical disorders, in particularly hematological malignan-
cies, provides important data for elucidating the regulatory 
mechanisms in hematopoiesis.
Challenges in interpreting controversial pathways 
in modern scheme of hematopoiesis based on stu-
dying immunophenotype of leukemia blast cells. 
In the group of acute leukemias of ambiguous lineage, 
the recent WHO classification [18] delineates the acute 
undifferentiated leukemia without expression of lineage-
specific antigens and the leukemias co-expressing 
antigens of several lineages at the levels not sufficient 
for identifying precisely the lineage of blast cells (acute 
leukemia with mixed phenotype, including B/myeloid 
leukemia, T/myeloid leukemia, lymphoblastic leukemia/
lymphoma from NK-cells). Study of these leukemias may 
be the challenging area of research allowing for new insight 
into the origin of lymphoid cell lineages.
The biphenotypic acute leukemias are believed to arise 
from MPP cells with the capability of diffe rentiating along 
both myeloid and lymphoid lineages. Previously, Matutes 
et al. [20] have been shown that the most common im-
munophenotype of biphenotypic acute leukemias is a co-
expression of B-lymphoid and myeloid markers and much 
less frequently, T-lymphoid and myeloid markers, while 
the cases with a B and T lymphoid phenotype or with tri-
lineage differentiation are exceptional. In fact, the same 
has been demonstrated in our diagnostic studies provided 
in Ukraine throughout several decades [21]. In some pa-
tients with ALL from early B-cells progenitors (pro-B-ALL, 
ALL of “common” type), the co-expression of a series 
of myeloid antigens (CD33, CD13, CD15) was detected 
that is in line with the modern concept of the persistence 
of myeloid potential in lymphoid lineage branches. Never-
theless, in various immunological variants of ALL of B-cell 
origin, we have never observed the co-expression of T-cell 
antigens on the blasts. Similarly, in T-ALL/T-cell lym-
phoma, the blast cells have never expressed the markers 
characteristic of B-cell immunophenotype.
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Study of blast crisis (BC) in the terminal phase 
of chronic myelogenous leukemia (CML) is also relevant 
to the issue of the origin of T cell lineage. This final phase 
in the evolution of CML behaves like an acute leukemia 
of myeloid (70% of cases) or lymphoid (30% of cases) 
types. In lymphoid type of BC CML, blast cells are ex-
clusively of B cell lineage with occasional co-expression 
of myeloid antigens but very rare if ever expression of T cell 
antigens. The blast cells of T cell phenotype in BC CML 
have been never detected in our studies [21]. This is again 
in line with the data that cells with double expression 
of B and T cell antigens have been never found in CLP 
populations in normal hematopoiesis [11]. Therefore, the 
fact that blast cells simultaneously exhibiting T-cell and 
B-cell surface antigens have not been observed both 
in acute leukemias and in BC CML contradicts to the con-
cept of CLP as the common progenitor cell for B cell and 
T cell lineages.
Some features of acute leukemias may be also con-
sidered as the helpful hints of the origin of NK cells. In our 
studies some similarity between blast cells in pro-B-ALL 
[МPО−, HLA-DR+, CD34+ (less than 50% of cells), CD19+ 
and CD33− (or their co-expression), t (4;11), 11q23] and 
acute monoblastic leukemia (AML M5a) [МPО−, HLA-
DR+/−, CD34+/−, CD33+ and CD19− (or their co-expression), 
t (9;11), 11q23] was found out [21]. Such similarities 
of immunophenotypic features and cytogenetic abnor-
malities in blast cells in pro-B-ALL and AML M5a seem 
to be the hint explaining for us three cases of AML M5a 
that were presented as a relapse of leukemia in children 
originally diagnosed as pro-B-ALL [23]. In some acute 
leukemia patients, the blasts with expression of marker 
signs of NK-cells and monocytes were detected. In our 
experience, the aberrant expression of CD7 and CD56 ob-
served in 32% cases of acute monoblastic leukemia was 
indicative of unfavorable course of the disease.
In our opinion, bipotent cells-progenitors of B-lym-
phocytes/monocytes and NK-cells/monocytes originate 
from oligolineage progenitors of lymphocytes/mono-
cytes. At the next stage of development, the unipotent 
progenitors — pro-B-lymphocytes, pro-NK-cells and 
promonocytes arise,  correspondingly. This is consistent 
with dual monocyte origin postulated in the studies of nor-
mal hematopoiesis [13]. The data on the clonal analysis 
of human acute leukemias/lymphomas with B cell/my-
elomonocytic phenotypes [22] also support the possible 
existence of B cell/myelomonocytic bipotent progenitors.
To sum up, the data based on cytochemical and immu-
nophenotypical signs of leukemic blast cells may be con-
sidered as reminiscent of the  corresponding data pertinent 
to normal hematopoiesis. In our opi nion, the analysis 
of the assembly of such data may be useful in solving some 
controversies in the modern schemes of hematopoiesis 
and even in amending modern hie rarchic model of normal 
hematopoiesis. On the other hand, the refined schemes 
of normal hematopoiesis might represent a good basis for 
improvements and even revisions in up-to-date classifica-
tions of the tumors of hematopoietic and lymphoid tissues.
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